Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) — 分析摘要
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)(HLN)的市值为43.42十亿美元,最近一年的营收同比增长了+1.3%。净利润率为15.2%。当前市盈率为19.6倍。
核心要点
- 营收同比变化+1.3%
- 净利润率15.2%
- 市盈率19.6倍
HLN的营收增长为+1.3%,市盈率为19.6倍。
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号,应与估值结果一并解读。
流动比率为 0.92x — 流动负债超过流动资产
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
员工人数
24,524
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$0.27
股息收益率
2.75%
股息历史
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。